Cardiol Therapeutics Inc. (CRDL) stock
CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.86−0.02 (-2.28%)
Close on Nov 20, 2026Market cap $86.48MP/E –Yield –
Cardiol Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -C$34.32M. The highest annual figure on record is -C$20.69M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -C$34.32M | – |
| FY2024 | Dec 31, 2024 | -C$40.28M | – |
| FY2023 | Dec 31, 2023 | -C$29.79M | – |
| FY2022 | Dec 31, 2022 | -C$41.34M | – |
| FY2021 | Dec 31, 2021 | -C$38.66M | – |
| FY2020 | Dec 31, 2020 | -C$20.69M | – |
See a number that looks wrong?